Barclays
KPTI icon

Barclays’s Karyopharm Therapeutics KPTI Stock Holding History

Barclays’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,400
Closed -$326K – 6947
2017
Q2 		$326K Buy
+2,400
New +$355K ﹤0.01% 3921

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's KPTI Position: Q2 2026 in Review

Barclays increased its Karyopharm Therapeutics (KPTI) stake by 2,135% in Q2 2026, buying an estimated $1.37M and bringing the position to 165,904 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2473.

Barclays first reported a position in KPTI in Q4 2013 and has held it in 51 quarters since. The position peaked at $11.1M in Q1 2023. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Barclays held 165,904 shares of Karyopharm Therapeutics worth $1.62M as of Q2 2026.
  • Barclays bought 158,480 Karyopharm Therapeutics shares in Q2 2026, an estimated $1.37M.
  • Karyopharm Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2473 holding.
  • Barclays first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 51 quarters since.
  • Barclays's Karyopharm Therapeutics position peaked at $11.1M in Q1 2023.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.